Browsing Tag
Antengene Corporation Limited
1 post
Antengene–UCB autoimmune deal: Why the $1.1bn ATG-201 partnership could reshape B-cell targeting therapies
Antengene licenses ATG-201 to UCB in a $1.1B autoimmune drug deal. Discover why bispecific antibodies are becoming the next frontier in immunology.